SG11202110270YA - Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers - Google Patents

Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers

Info

Publication number
SG11202110270YA
SG11202110270YA SG11202110270YA SG11202110270YA SG11202110270YA SG 11202110270Y A SG11202110270Y A SG 11202110270YA SG 11202110270Y A SG11202110270Y A SG 11202110270YA SG 11202110270Y A SG11202110270Y A SG 11202110270YA SG 11202110270Y A SG11202110270Y A SG 11202110270YA
Authority
SG
Singapore
Prior art keywords
inhibitors
protein kinase
hedgehog pathway
dependent cancers
atypical protein
Prior art date
Application number
SG11202110270YA
Inventor
Anthony E Oro
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of SG11202110270YA publication Critical patent/SG11202110270YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202110270YA 2019-03-28 2020-03-27 Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers SG11202110270YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825334P 2019-03-28 2019-03-28
PCT/US2020/025437 WO2020198670A1 (en) 2019-03-28 2020-03-27 Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers

Publications (1)

Publication Number Publication Date
SG11202110270YA true SG11202110270YA (en) 2021-10-28

Family

ID=72611927

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110270YA SG11202110270YA (en) 2019-03-28 2020-03-27 Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers

Country Status (12)

Country Link
US (1) US20220143028A1 (en)
EP (1) EP3947380A4 (en)
JP (1) JP2022527320A (en)
KR (1) KR20220002930A (en)
CN (1) CN114206865A (en)
AU (1) AU2020248096A1 (en)
BR (1) BR112021019204A2 (en)
CA (1) CA3135196A1 (en)
IL (1) IL286699A (en)
MX (1) MX2021011788A (en)
SG (1) SG11202110270YA (en)
WO (1) WO2020198670A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073964B2 (en) * 2011-05-06 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
MX2015004016A (en) * 2012-09-28 2016-02-18 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c.
US9192609B2 (en) * 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
TWI675836B (en) * 2014-03-25 2019-11-01 美商伊格尼塔公司 Azaquinazoline inhibitors of atypical protein kinase c
US11406643B2 (en) * 2017-08-11 2022-08-09 Board Of Regents, The University Of Texas System Targeting kinases for the treatment of cancer metastasis

Also Published As

Publication number Publication date
CN114206865A (en) 2022-03-18
EP3947380A4 (en) 2023-01-11
WO2020198670A1 (en) 2020-10-01
IL286699A (en) 2021-12-01
JP2022527320A (en) 2022-06-01
EP3947380A1 (en) 2022-02-09
BR112021019204A2 (en) 2021-11-30
AU2020248096A1 (en) 2021-10-14
MX2021011788A (en) 2022-01-24
KR20220002930A (en) 2022-01-07
CA3135196A1 (en) 2020-10-01
WO2020198670A9 (en) 2020-11-19
US20220143028A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
SG11202010977QA (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
IL277665A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284324A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL287751A (en) Kcnt1 inhibitors and methods of use
IL279475A (en) Ectonucleotidase inhibitors and methods of use thereof
IL276711A (en) Arginase inhibitors and methods of use thereof
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287973A (en) Acss2 inhibitors and methods of use thereof
IL287043A (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
IL281999A (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
IL277918A (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
IL280924A (en) Arginase inhibitors and methods of use thereof
EP3576766A4 (en) Cyclin g1 inhibitors and related methods of treating cancer
EP3498274C0 (en) Application of phosphodiesterase 4 inhibitor zl-n-91 in preparation of medicament for treating prostate cancer proliferation and metastasis
IL286149A (en) Caspase inhibitors and methods of use thereof
EP3595664A4 (en) Indazole inhibitors of fructokinase (khk) and methods of use in treating khk-mediated disorders or diseases
IL286699A (en) Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers
EP3654967A4 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
IL268771A (en) Peptide kinase inhibitors and methods of use thereof
GB201621472D0 (en) Inhibitors of ataxia-tellangiectasia mutated and rad3-related protein kinase (ATR) for use in methods of treating cancer